ASAP Act
- Sponsor
- Rep. Buchanan, Vern [R-FL-16]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Sep 16, 2026
Bottom line
The bill aims to enable earlier diagnosis and intervention for Alzheimer's and related dementias by mandating Medicare coverage for advanced, FDA-approved screening tests.
What it actually does
This bill expands Medicare coverage to include blood-based and other biospecimen-based early detection screening tests for Alzheimer's disease and related dementias, effective January 1, 2028. It specifies that these tests must be approved or cleared by the FDA and broadly defines eligible test types, including genomic sequencing, single-analyte, and multiplex panel tests, as well as medical imaging based on biospecimens.
Proponents argue
Proponents argue that early detection of Alzheimer's and related dementias is crucial for timely interventions, treatment planning, and improving patient outcomes, potentially slowing disease progression and reducing long-term care costs. They highlight the potential for new blood-based tests to be less invasive and more accessible than current diagnostic methods, offering a significant step forward in managing this devastating disease.
Opponents contend
Opponents might raise concerns about the potential cost implications for Medicare, especially given the broad definition of covered tests and the future effective date, which could lead to significant expenditures. They may also question the clinical utility and accuracy of some emerging early detection tests, or the readiness of the healthcare system to manage a potential surge in early diagnoses without robust treatment options.
The bill is very short and straightforward, making it highly accessible for a quick review by any interested party.
Section 2(a)(1) and (2) of the bill, amending Section 1861(s)(2) and adding new subsection 1861(nnn) of the Social Security Act.
Establishes Medicare Coverage for Alzheimer's and Related Dementias Early Detection Screening Tests
This provision expands Medicare Part B benefits to include new early detection screening tests for Alzheimer's disease and related dementias. It defines these tests as those cleared or approved by the FDA, including genomic sequencing blood tests and other equivalent blood, tissue, or urine-based tests, as well as medical imaging, with coverage effective January 1, 2028.
Supporters argue
Supporters argue this coverage is critical for shifting dementia care towards early intervention, which can improve patient quality of life, allow for earlier treatment, and facilitate better care planning. They emphasize the potential for these tests to reduce the burden on families and the healthcare system in the long run.
Critics contend
Critics might express concern over the potential for over-diagnosis or false positives, leading to unnecessary anxiety and further medical procedures. They may also highlight the lack of widely available curative treatments for early-stage Alzheimer's, questioning the immediate clinical utility of widespread early screening.
Tradeoffs
The bill balances the desire for early detection and intervention against potential costs to the Medicare system and the current limitations in effective treatments for early-stage dementia. It also navigates the balance between promoting innovation in diagnostic testing and ensuring clinical utility and cost-effectiveness.
Section 2(b) of the bill, amending Section 1833(h)(1)(A) of the Social Security Act.
Establishes Payment Mechanism for New Screening Tests
This provision ensures that the newly covered Alzheimer's and related dementias early detection screening tests will be paid for under the existing Medicare Part B payment methodology for clinical diagnostic laboratory tests. This integrates the new coverage into the established reimbursement framework, providing clarity for providers.
The bill allows the Secretary of Health and Human Services to determine other 'equivalent tests' for early detection of Alzheimer's and related dementias, beyond genomic sequencing blood tests. This includes a wide range of technologies like single-analyte tests, cell-free nucleic acids, multiplex panels, whole genome/exome/transcriptome, protein expression, and medical imaging based on various biospecimens.
Section 2(a)(2), new subsection 1861(nnn)(2)(B) of the Social Security Act.
Why it matters:This is standard legislative practice to provide flexibility for future technological advancements without requiring new legislation. It allows the Secretary to adapt coverage as science evolves.
Case for: Supporters argue this flexibility is crucial for future-proofing the legislation, ensuring Medicare can cover new, more effective diagnostic technologies as they emerge without needing further congressional action. It promotes innovation and keeps pace with scientific progress.
Case against: Critics might argue that such broad discretion given to the Secretary could lead to coverage of tests whose clinical utility or cost-effectiveness is not yet fully established, potentially increasing Medicare expenditures significantly without sufficient oversight.
Estimated impact: This provision could significantly expand the scope and cost of covered tests over time, depending on future technological developments and secretarial determinations.
The new Medicare coverage for early detection screening tests for Alzheimer's and related dementias will apply 'on or after January 1, 2028.'
Section 2(a)(2), new subsection 1861(nnn) of the Social Security Act.
Why it matters:This is a common legislative practice to specify the start date of a new program or benefit directly within its definition. The delay allows time for regulatory implementation, FDA approvals, and healthcare system preparation.
Case for: Proponents would argue that a delayed effective date provides ample time for the Centers for Medicare & Medicaid Services (CMS) to develop appropriate coverage policies, for the FDA to review and approve new tests, and for healthcare providers to integrate these screenings into their practices. This ensures a smoother rollout.
Case against: Some might argue that delaying coverage until 2028 postpones access to potentially life-changing early detection for beneficiaries who could benefit sooner, especially given the urgency of addressing Alzheimer's disease.
Estimated impact: The delay shifts the fiscal impact of the new coverage to future fiscal years, allowing for more time to prepare for the budgetary implications.